Semaglutide not working. what to check first. - Reddit

Are you at a therapeutic dose?

Semaglutide for weight management is titrated upward over months. The starting dose (typically 0.25 mg weekly) is a tolerability step, not a therapeutic dose. Most patients do not experience meaningful appetite suppression until they reach 1 mg or higher. If you have been on the medication for less than eight weeks or have not yet moved beyond the initial starting dose, the drug has not yet had the opportunity to demonstrate its full effect.

The pivotal STEP 1 trial, which studied semaglutide 2.4 mg weekly, used a 16-week titration period before participants reached the maintenance dose. Dose impatience — stopping or concluding ineffectiveness before the titration is complete — is one of the most common reasons patients feel semaglutide is not working.

If you have been titrating for several months and still feel no appetite suppression at escalating doses, that is a different situation — and worth a direct conversation with your clinician about whether to continue or explore alternative approaches.

Could injection technique and site be the problem?

Subcutaneous injection errors are a common but underappreciated cause of inconsistent semaglutide response. The medication needs to reach subcutaneous fat tissue — not muscle (too deep), not skin surface (too shallow).

• Recommended sites: Lower abdomen (at least 2 inches from the navel), outer thigh, or outer upper arm. All three have adequate subcutaneous tissue for reliable absorption.
• Rotate sites: Injecting into the same spot repeatedly creates lipohypertrophy — hardened, fibrous tissue that absorbs medication more slowly and variably. Rotate systematically.
• Needle length: Most people use a 4–8 mm pen needle. Very lean individuals may need 4 mm to avoid intramuscular injection; individuals with more subcutaneous tissue can use 6–8 mm.
• Storage: Semaglutide must be refrigerated. A pen that has been exposed to heat, frozen, or used past expiration may be degraded and will underperform regardless of technique.

Can diet choices make semaglutide stop working?

Semaglutide works primarily by slowing gastric emptying, reducing appetite through GLP-1 receptor activation in the hypothalamus, and increasing feelings of fullness. But several dietary patterns are highly effective at working around this mechanism:

• Liquid calories:Sodas, juices, protein shakes, alcohol, and specialty coffee drinks bypass gastric emptying entirely. Patients who switch from solid meals to calorie-dense liquids often do not feel the medication’s appetite-suppressing effect because they are not registering fullness from stomach stretch.
• Hyperpalatable processed foods: Ultra-processed foods engineered for overconsumption can override satiety signals from multiple pathways, including GLP-1 activation. If your diet remains high in processed snack foods, the appetite suppression from semaglutide may be partially masked.
• Alcohol: Alcohol is calorie-dense, lowers inhibitions around food, and can trigger nausea that is mistaken for medication side effects. Reducing or eliminating alcohol is one of the highest-leverage dietary changes for patients not seeing expected results.

A useful self-audit: log calories for 3–5 days without changing behavior. Many patients discover that liquid calorie intake is substantially higher than estimated, which explains a gap between medication effectiveness and observed weight change.

Why does semaglutide seem to stop working after initial weight loss?

Plateaus after initial progress are nearly universal with all weight-loss interventions, including GLP-1 medications. The body adapts: resting metabolic rate decreases as body weight falls, and the caloric deficit that produced results initially is smaller in absolute terms once you are at a lower weight.

The STEP 1 trial showed that most weight loss occurred in the first 60 weeks, with a gradual deceleration after that. A plateau is not evidence that semaglutide has stopped working — it is evidence that the body has adapted to the new equilibrium. Breaking a plateau typically requires one or more of the following:

• Recalculating caloric targets based on current body weight, not starting weight
• Adding or increasing resistance training to protect and build lean muscle mass, which raises resting metabolic rate
• Discussing a dose adjustment with your clinician if you are not at the maximum maintenance dose
• Reviewing protein intake — higher protein (1.2–1.6 g per kg of body weight) helps preserve lean mass during a caloric deficit

Compounded vs. branded: does the source matter?

Patients accessing semaglutide through compounding pharmacies sometimes wonder whether product quality explains a lack of response. Quality varies by pharmacy. Semaglutide compounded in the USA by a licensed 503A pharmacy using pharmaceutical-grade active pharmaceutical ingredient (API) should be bioequivalent to branded formulations when properly stored. Semaglutide from unverified sources — overseas suppliers, gray-market vendors, or "research chemical" sellers — is a different matter entirely, with no guarantee of purity, concentration accuracy, or sterility.

If your semaglutide was obtained outside a licensed medical channel, product quality is a legitimate variable to consider. If it came from a licensed 503A pharmacy through a clinical prescription, the compounding source is unlikely to be the primary explanation.

When should you contact your clinician?

Contact your clinician — not a forum or a social media group — if you are experiencing any of the following:

• Zero appetite suppression after 4–6 weeks at a consistent dose, with confirmed proper injection technique
• A plateau lasting more than 8–12 weeks despite dietary and exercise adherence
• Persistent nausea or gastrointestinal side effects that are interfering with eating and making dietary adherence difficult
• Concerns about whether your current dose is appropriate for your body weight and clinical goals

Clinician-supervised weight management allows for dose adjustments, medication holidays, and protocol changes that are not available to patients self-managing. The relationship with a prescribing clinician is one of the most under-utilized assets in GLP-1 therapy.

Frequently asked questions